Cannabis marketing aimed at women's health has expanded rapidly, covering menstrual pain, endometriosis, menopause and sexual wellness. The research has not kept pace, and the gap is wide enough that it is worth going condition by condition.
One area has an unambiguous answer, so it comes first.
Pregnancy and Breastfeeding: A Clear No
This is not a close call and it is the most common question.
Cannabis crosses the placenta. THC reaches fetal circulation, and the endocannabinoid system is involved in neurodevelopment, so exposure occurs during a period when the system is actively shaping brain formation.
Prenatal cannabis exposure is associated with lower birth weight, and studies have reported associations with attention, behavioural and cognitive differences in childhood. Confounding by tobacco, alcohol and socioeconomic factors complicates the research, and the consistency of the birth weight finding and the plausibility of the developmental concern have led major obstetric bodies to advise against use in pregnancy.
Breastfeeding. THC is lipophilic and passes into breast milk, where it has been detected for days after use, with reports of detection up to around six days. Infant metabolism is immature. The advice is to avoid cannabis while breastfeeding.
The frequent objection is that cannabis helps severe pregnancy nausea. Hyperemesis gravidarum is genuinely awful and there are better-studied treatments for it. This is the situation to escalate with an obstetric provider rather than self-treat.
Menstrual Pain
Cannabis has a long informal history here, and the direct evidence is thin.
Primary dysmenorrhoea involves prostaglandin-driven uterine contraction, which is why NSAIDs work well by inhibiting prostaglandin synthesis. Cannabinoids do not act on that mechanism, so any benefit is likely analgesic and muscle-relaxant rather than targeting the cause.
Survey data reports that many people use cannabis for period pain and describe relief. There are essentially no controlled trials. NSAIDs, hormonal contraception and heat have better support, and cannabis is a reasonable adjunct rather than a first option.
A note on the frequently repeated claim that Queen Victoria was prescribed cannabis for menstrual cramps: this is not well documented and is best treated as folklore rather than evidence.
Endometriosis
Endometriosis involves endometrial-like tissue growing outside the uterus, causing pain, inflammation and often infertility. Pain is frequently severe, treatment options are unsatisfying, and diagnostic delay of years is common. That combination explains why cannabis use is widespread in this group.
Survey and observational studies, including patient-reported outcome research, consistently report that people with endometriosis using cannabis describe meaningful reductions in pelvic pain and improved sleep, often alongside reduced use of other analgesics.
There are no adequately powered randomised trials. The mechanistic rationale is reasonable, since endometriosis pain involves both inflammation and central sensitisation, and cannabinoids act on pain processing. It remains unproven, and given how poorly served these patients are by existing options, it is a legitimate research priority.
Cannabis does not treat the underlying disease. Surgical and hormonal management remain the disease-directed options.
Menopause
Surveys report substantial cannabis use among menopausal and perimenopausal women, mainly for sleep disturbance, hot flushes, mood and joint pain.
There is no trial evidence that cannabis reduces vasomotor symptoms. Sleep and anxiety benefits are plausible on general grounds. Hormone therapy has strong evidence for vasomotor symptoms and its risk profile has been substantially reassessed in recent years, which makes it worth revisiting with a clinician rather than dismissing.
One genuine consideration is bone health. Menopause accelerates bone loss, and some research associates heavy cannabis use with lower bone mineral density. That is a reason for caution about heavy long-term use in this group specifically.
Fertility
Evidence is limited and the direction of concern is consistent.
The endocannabinoid system participates in reproductive signalling, including ovulation and implantation. Research has associated cannabis use with disrupted ovulation and menstrual cycle irregularity, and some studies report longer time to conception among users.
Anyone actively trying to conceive has a reasonable case for stopping, on precautionary grounds rather than proven harm.
Suppositories and Sexual Wellness
Vaginal and rectal cannabis suppositories are marketed for pelvic pain and sexual discomfort. Absorption pharmacology for these routes is poorly characterised, claims about avoiding intoxication are not reliably supported, and trial evidence is absent.
Products for sexual wellness rest largely on user report. Some report enhanced sensation and reduced anxiety, both plausible from general cannabis effects rather than anything specific.
Bottom Line
Avoid cannabis in pregnancy and while breastfeeding, where the advice is clear and consistent. Endometriosis has the strongest patient-reported signal and no trials, which makes it the most reasonable candidate for careful use and the most urgent research gap. Menstrual pain has better-supported alternatives. Fertility is a precautionary reason to stop. Everything else in this category is running on survey data and marketing.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before making any health-related decisions.